Literature DB >> 14981231

Consensus development conference on antipsychotic drugs and obesity and diabetes.

.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2004        PMID： 14981231     DOI： 10.1038/oby.2004.46

Source DB:  PubMed          Journal:  Obes Res        ISSN： 1071-7323


× No keyword cloud information.
  13 in total

1.  The effectiveness of cross-tapering switching to ziprasidone in patients with schizophrenia or schizoaffective disorder.

Authors:  Young-Hoon Ko; Kyoung-Sae Na; Chul-Eung Kim; Seung-Hyun Kim; Yang-Whan Jeon; Jung-Seo Yi; Moon-Soo Lee; Shin-Gyeom Kim; Hyun-Ghang Jeong; Han-Yong Jung
Journal:  Psychiatry Investig       Date:  2014-10-20       Impact factor: 2.505

Review 2.  The efficacy and safety of switching to ziprasidone from olanzapine in patients with bipolar I disorder: an 8-week, multicenter, open-label study.

Authors:  Hwang-Bin Lee; Bo-Hyun Yoon; Young-Joon Kwon; Young Sup Woo; Jung-Goo Lee; Moon-Doo Kim; Won-Myong Bahk
Journal:  Clin Drug Investig       Date:  2013-10       Impact factor: 2.859

3.  Prognosis in obesity: obesity in severe mental illness poses particular problems.

Authors:  Paul Mackin; Allan H Young
Journal:  BMJ       Date:  2005-08-20

4.  Antipsychotic Cardiometabolic Side Effect Monitoring in a State Community Mental Health System.

Authors:  Robert O Cotes; Alex de Nesnera; Michael Kelly; Karen Orsini; Haiyi Xie; Greg McHugo; Stephen Bartels; Mary F Brunette
Journal:  Community Ment Health J       Date:  2015-02-03

5.  A parametric analysis of olanzapine-induced weight gain in female rats.

Authors:  G D Cooper; L C Pickavance; J P H Wilding; J C G Halford; A J Goudie
Journal:  Psychopharmacology (Berl)       Date:  2005-10-15       Impact factor: 4.530

Review 6.  Hepatic Safety of Atypical Antipsychotics: Current Evidence and Future Directions.

Authors:  Mahmoud Slim; Inmaculada Medina-Caliz; Andres Gonzalez-Jimenez; M Rosario Cabello; Fermin Mayoral-Cleries; M Isabel Lucena; Raul J Andrade
Journal:  Drug Saf       Date:  2016-10       Impact factor: 5.606

7.  Influence of MCHR2 and MCHR2-AS1 Genetic Polymorphisms on Body Mass Index in Psychiatric Patients and In Population-Based Subjects with Present or Past Atypical Depression.

Authors:  Aurélie Delacrétaz; Martin Preisig; Frederik Vandenberghe; Nuria Saigi Morgui; Lina Quteineh; Eva Choong; Mehdi Gholam-Rezaee; Zoltan Kutalik; Pierre Magistretti; Jean-Michel Aubry; Armin von Gunten; Enrique Castelao; Peter Vollenweider; Gerard Waeber; Philippe Conus; Chin B Eap
Journal:  PLoS One       Date:  2015-10-13       Impact factor: 3.240

8.  Barriers to monitoring and management of cardiovascular and metabolic health of patients prescribed antipsychotic drugs: a systematic review.

Authors:  Ruba Azfr Ali; Zahraa Jalal; Vibhu Paudyal
Journal:  BMC Psychiatry       Date:  2020-12-04       Impact factor: 3.630

9.  Diabetic control and atypical antipsychotics: a case report.

Authors:  Romina Lopez Gaston; Mohan George; Nangai Azhahan
Journal:  J Med Case Rep       Date:  2008-05-14

10.  Minding metabolism: targeted interventions to improve cardio-metabolic monitoring across early and chronic psychosis.

Authors:  John R Kelly; Priyola Gounden; Aoibheann McLoughlin; Zahra Legris; Therese O'Carroll; Roisin McCafferty; Liliana Marques; Maeve Haran; Richard Farrelly; Karen Loughrey; Gráinne Flynn; Aiden Corvin; Catherine Dolan
Journal:  Ir J Med Sci       Date:  2021-03-08       Impact factor: 1.568
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.